NewsBenzingaNkarta社、進行中のNtrust臨床試験プログラムにおいてNKX019(同種由来の即製CD19標的CAR-NK細胞療法候補)で治療された40人の患者から得られた統合安全性結果を発表 Nkarta社、進行中のNtrust臨床試験プログラムにおいてNKX019(同種由来の即製CD19標的CAR-NK細胞療法候補)で治療された40人の患者から得られた統合安全性結果を発表 Benzinga 2026.11.11 12:03 (GMT+0) Open on Benzinga Other news CalPERS Discloses $37.1 Million Stake in Strategy Scammers Used Musk Deepfake Video to Defraud; Coinbase AI System Blocked $4.7 Million JPMorgan Is Developing AI Agent Trading Without Human Involvement Coinbase CEO: AI Agents to Account for Well Over 99.9% of Trading Volume Within a Decade; Bitcoin May Have Bottomed This Cycle Jito CEO: Crypto Developers Should Slow Down in the Next Two Years and Focus on Fixing Security Flaws Glassnode: Bitcoin Sell-Off Nears Historical Local Bottom Levels, $62,000 Becomes Key Line of Defense
Coinbase CEO: AI Agents to Account for Well Over 99.9% of Trading Volume Within a Decade; Bitcoin May Have Bottomed This Cycle
Jito CEO: Crypto Developers Should Slow Down in the Next Two Years and Focus on Fixing Security Flaws
Glassnode: Bitcoin Sell-Off Nears Historical Local Bottom Levels, $62,000 Becomes Key Line of Defense